INTRODUCTION
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults. The incidence of RCC has been rapidly increasing for the last 20 years, and is increasingly being discovered at earlier stages. 1 It was estimated that there were 1 660 290 new cases of RCC in the USA in 2013 with almost 580 350 deaths. 2 In 2010, the American Joint Committee on Cancer suggested a new clinical stage system in which RCC is divided into four stages. Clear cell carcinoma has the two most frequent subtypes: clear cell renal cell carcinoma (cRCC, 80%) and clear cell papillary cell carcinoma ( pRCC, 10%-15%). Because there are limited early warning signs, most patients are at an advanced state when they are diagnosed, and the cancer's resistance to chemotherapy or radiotherapy makes treating these patients rather difficult. Therefore, it is essential to find a new method to predict the prognosis of cRCC. Investigating the mechanisms underlying the carcinogenesis of cRCC may provide more sophisticated early diagnostic and further therapeutic strategies.
Immunoglobulin (Ig) is the most classical immune molecule family. Since 500 million years ago, Ig has become more complex. This development has resulted in the formation of complicated structures of different types, and infinite varieties can be found in the variable region. However, Ig strictly acts as an antibody and is only secreted from B lineage cells. In recent years, various pieces of evidence have revealed that Igs including IgM, IgG and IgA, can be expressed in many non-B cell lineages, such as epithelial cells, germ cells and neurons. [3] [4] [5] [6] [7] Importantly, non-B-cell-derived Ig's, especially the IgG, have frequently been found to be overexpressed in many cancer cell types, including breast cancer, colon cancer, lung cancer, liver cancer, stomach cancer, cervical cancer, pancreatic cancer, ovarian cancer and prostate cancer. 3 8-13 Furthermore, unlike classical IgG, which has an antibody function, cancer cell-derived IgG is mainly involved in the survival and progression of cancer cells.
In our previous studies, commercial antibodies against IgG could mainly recognise the circulating IgG, but they were not specific for the non-B-cell-derived IgG. RP215 was originally generated by Lee et al 14 using the cell lysate of ovarian cancer cell line OC-3-VGH as an immunogen. We identified that antibody RP215 specifically recognises a glycosylated epitope of non-B cell expressed IgG heavy chain (RP215-recognised IgG). [15] [16] [17] In this study, we found that the IgG recognised by RP215 was expressed in renal carcinoma cells. Knockdown of IgG in renal carcinoma cell lines resulted in significant inhibition of cancer cell proliferation, migration and invasion. Importantly, using RP215, we found that high IgG expression was significantly correlated with poor differentiation and advanced stage.
MATERIALS AND METHODS Tissue microarray
The tissue microarray, including 75 different cases of cRCC and adjacent normal kidney tissues, were purchased from Shanghai Outdo Biotech (Shanghai, China). The Fuhrman grade (WHO 1997) guided the grade of this study. Fuhrman grade is the most widely accepted histological grading system in RCC. The methods: I, small, round, uniform nuclei with inconspicuous or absent nucleoli; II, larger nuclei with irregular outline and small nucleoli; III, larger nuclei with irregular outline and prominent nucleoli; IV, grade III features with bizarre, multinucleated cells, with or without spindle cells.
The tissue of breast cancers and lymph nodes were obtained from patients in at Peking University People's Hospital.
Ethics statement
This study was approved by the ethics committee of Peking University People's Hospital. All patients provided written informed consent.
Cell culture
Three renal carcinoma cell lines (CAKI-I, 786-0 and ACHN) were obtained from American Type Culture Collection. Cells were cultured in RPMI 1640 (Hyclone, Logan, Utah, USA) medium supplemented with 10% fetal bovine serum (Hyclone) and incubated at 37°C in a humidified atmosphere containing 5% CO 2 .
Immunohistochemistry analysis
RP215 is provided by Gregory Lee of University of British Columbia in Vancouver, Canada. The sections containing clinical samples were dewaxed, rehydrated and then heated in 10 mmol/L citrate buffer ( pH 6.0) for antigen retrieval. After, the sections were washed in phosphate-buffered saline (PBS), blocked with 10% normal goat serum for 30 min and incubated with 15 mg/mL purified RP215 in a humidified chamber at 4°C overnight. Inmunodetection was performed using the Envision ABC Kit (Gene Tech Company, Shanghai, China). After staining with haematoxylin, the tissues were dehydrated and mounted. A pathologist evaluated the extent and intensity of RP215 staining independently and without clinical data. We used the breast cancer tissues as a positive control.
Both the relative number of positive cells and intensity of staining were assessed in five randomly chosen 200× microscopic fields. The percentage of stained cells per field was defined as the following: 0, negative; 1, 1%-25%; 2, 26%-50% and 3, 51%-100% of the cells. The staining intensity was scored on a four-tiered scale as follows: 0, absence of signal; 1, low-intensity signal (light brown); 2, moderate-intensity signal (brown) and 3, high-intensity signal (dark brown). The frequency score and intensity score were multiplied to obtain the score for each field, and the final score for each case was the average score of the five fields. The score for RP215 staining was described as negative (−) when the score was 0-1. 'Low expression' encompassed scores of 2-3 (+) while 'high expression' encompassed scores of 4-6 and 7-9 (++ and +++, respectively). All evaluations were conducted using a LEICA DM4000B/M microscope.
Immunofluorescence ACHN, 786-0 and CAKI-I cell lines that reached 60%-70% confluence prior to the test were seeded into the 12-well plates in 37°C incubators with 5% CO 2 . The cells were fixed with acetone for 5 min at room temperature. Then, the cells were blocked with 10% normal goat serum for 30 min and incubated with 25 mg/mL purified RP215 as a primary antibody at 4°C for 45 min; the cells were then incubated with the secondary antibody (1:400, polyclonal goat antimouse IgG-H&L; Abcam, Cambridge, UK) at 4°C for 30 min. Images were captured using the inverted fluorescence microscope subsequent to being mounted using 50% glycerine.
Western blot
Protein was extracted using lysis buffer (RIPA, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 1% sodium deoxycholate, 0.15 M NaCl and 10 mM Tris, pH 7.2). The protein concentration was assessed using Pierce BCA Protein Assay Kit (Thermo, Rockford, Illinois, USA). Protein samples (50 mg) were separated by electrophoresis in 12.5% sodium dodecyl sulfate-polyacrylamide gels and were then transferred onto a nitrocellulose membrane (Millipore, Bedford, Massachusetts, USA). The membrane was blocked in 5% non-fat milk for 1 h and incubated with primary antibodies (7.5 μg/mL) at 4°C over night. The blots were incubated with antimouse IgG horseradish peroxidase conjugate at room temperature for 1 h. Immunoreactive bands were visualised using Super Signal West Pico Chemiluminescent Substrate (Thermo).
siRNA and cell transfection
The siRNAs against Ig gamma chain constant region (siRNA1, 5 0 -GGUGGACAAGACAGUUGAG-3 0 and siRNA2, 5 0 -AGUGC AAGGUCUCCAACAA-3 0 ) and the non-silencing control RNA (NC, 5 0 -UUCUCCGAACGUGUCACGU-3 0 ) were produced and purchased from GenePharma (Shanghai, China). The siRNAs and NC were transferred into the 786-0 and ACHN cell line by Lipofectamine 2000 transfection reagent (Life Technologies, Grand Island, New York, USA) according to the manufacturer's instructions. The knockdown efficiency of IgG was verified by western blot analysis.
Reverse transcriptase-polymerase chain reaction
Total RNA of cRCC cell lines, CAKI-I, 786-0 and ACHN was extracted by TRIzol reagent and then reverse transcribed using RT-PCR RevertAid, First-Strand cDNA Synthesis Kit (Thermo) according to the manufacturer's instruction. The primers were IgG (forward, 5 0 -ACTACAAGACCACGCCTCC-3 0 ; reverse, 5 0 -CGTCGCACTCATTTACCC-3 0 ) and GAPDH (forward, 5 0 -CAAGGTCATCCATGACAACTTTG-3 0 ; reverse, 5 0 -GTCCA CCACCCTGTTGCTGTAG-3 0 ). PCR products were electrophoresed on 1.5% agarose gels containing 0.5 μg/mL ethidium bromide.
Cell proliferation assay
The 786-0 and ACHN cells were transfected with siRNA (50 mg/mL) in 96-well plates and incubated at 37°C. Cell proliferation was analysed using the CCK8 Cell Proliferation Assay Kit (Invitrogen, Carlsbad, California, USA). CCK8 reagent (5 mL) was added to each well and incubated for 2 h. The number of viable cells was calculated by absorbance measurements at 450 nm. Each condition was assessed in triplicate.
Cell apoptosis assay
786-0 and ACHN cells were cultured for 20 h and then treated with siRNA for 48 h. The cells were then harvested, washed with ice-cold PBS and stained with annexin V/PI (AV/PI) reagent as previously described. The percentage of annexin V cells was determined by flow cytometry. The percentage of annexin V cells indicates the frequency of total apoptotic cells.
Cell migration assay
The migration assay was performed in a 24-well transwell (Corning, Corning, New York, USA) containing a polycarbonate
5 of each group to add in the transwell chamber. Conditioned medium containing 10% fetal bovine serum was added to the bottom part of the chamber. The cells were incubated in a 5% carbon dioxide incubator at 37°C for 24 h. After incubation, cells in the upper chamber that were attached but had not migrated were scraped off, and the migrated cells on the bottom of the filter were fixed with methanol and stained with haematoxylin. The number of cells was counted in at least six randomised fields under a microscope. Results were obtained from at least three individual experiments.
Cell invasion assay
The invasion assay was performed in a 24-well invasion (Corning) containing a polycarbonate filter (8 μm pore size). The 786-0 and ACHN cells were counted as 10 5 of each group to add in the invasion chamber. Conditioned medium containing 10% fetal bovine serum was added to the bottom part of the chamber. The cells were incubated in a 5% carbon dioxide incubator at 37°C for 24 h. After incubation, cells in the upper chamber that were attached but had not migrated were scraped 
RESULTS

IgG was expressed in the cRCC cells
In this study, the IgG staining was detected in cRCC cell lines (CAKI-I, 786-0 and ACHN) by IF. We found IgG staining in the cell cytoplasm, filopodia structure and extracellular area ( figure 1A) . Immunohistochemistry also showed that positive staining of IgG was frequently located in the cytoplasm of cancer cells in cRCC tissues (66/75, 88%) and in the adjacent normal kidney tissues (63/75, 84%). The breast cancer tissues were used as the positive control (figure 1B:c). Importantly, IgG and its functional transcripts were also confirmed in cRCC cell lines by western blot and RT-PCR ( figure 1C, D) .
Knockdown of IgG significantly reduced the proliferation of both 786-0 cells and ACHN cells
To investigate whether IgG is responsible for cell proliferation in cRCC cells, we designed two siRNAs to knockdown IgG expression in cRCC cell lines (786-0 and ACHN) and analysed the cell proliferation ability. Our results showed that the cell proliferation ability was significantly downregulated after the knockdown of IgG heavy chain expression in 786-0 and ACHN cells (figure 2).
Knockdown of IgG significantly reduced apoptosis in 786-0 cells, but not in ACHN cells
We also wondered whether IgG is also involved in apoptosis in cRCC cell lines. Cultured 786-0 and ACHN cell lines were stained by AV/PI after knockdown of IgG. We found that knockdown of IgG could significantly induce apoptosis of 786-0 cells, which was not the case for ACHN cells ( figure 3) . These results suggested that IgG knockdown reduced the survival of 786-0 but not ACHN cells.
Knockdown of IgG significantly reduced the migration of both 786-0 and ACHN cells
After we found that knockdown of IgG could induce the migration of the 786-0 cells and ACHN cells, we aimed to determine whether IgG is involved in the migration of cRCC cells by performing transwell assays with the same number of 786-0 and ACHN cells in each group. The ability of migration was significantly inhibited after knocking down IgG heavy chain in 786-0 and ACHN cells (figure 4).
The invasion ability of both 786-0 and ACHN cells was also reduced by siRNA
We also examined whether IgG is also involved in the invasion of cRCC cells. We performed invasion assays in 24-well invasion chambers using the same number of 786-0 and ACHN cells in each group. We also found that after IgG expression was knocked down in both 786-0 and ACHN cells, the number of invading cells was significantly decreased (figure 5). Figure 3 The apoptosis of clear cell renal cell carcinoma cells was induced by specific siRNA for IgG. IgG knockdown could significantly induce the apoptosis of 786-0 cells, but not in the ACHN cells by FACS using the siRNA-1-specific and siRNA-2-specific siRNA for IgG.
IgG expression is significantly correlated with poor differentiation and an advanced stage of cRCC
We analysed whether IgG expression is correlated with the poor differentiation, tumour size and advanced stage of cRCC using immunohistochemistry. There was a higher positive rate of IgG staining in patients with histological grades III-IV (34/ 35, 97.1%) than in patients with histological grades I-II (80.0%, 32/40), and there was a significant difference between the patients with high and low grades ( p<0.05) ( figure 6A ). Comparing the positive frequency between a larger tumour size (>7 cm) and smaller tumour size (≤7 cm), we found that the positive rate of patients with a large tumour was 94% (31/ 33), which had a higher frequency than patients with smaller tumours (35/42, 83.3%; p<0.05) (figure 6B). More importantly, IgG expression was significantly related to the recurrence of cRCC. A strong positive rate (≥++ and +++) was observed in 87.0% (20/23) of patients with stages III-IV of cRCC, while a strong positive rate was observed in only 48% (25/52) of patients with stages I-II (p<0.05) ( figure 6C and  table 1 ). Gender may also be related to IgG expression (p<0.05), but there is no relationship between the IgG expression and age. The median survival time for IgG strong positive staining group was 40.1176 months; while the median survival time for IgG weak positive staining group was 49.0220 months.
Correlation between non-B-IgG expression and survival in patients with cRCC
The correlation of non-B-IgG expression and 7-year overall survival of patients with cRCC was elevated according to the results of Kaplan-Meier analysis. The survival of patients with weak positive (negative and '+') IgG staining was significantly Figure 4 IgG knockdown significantly detected the migration of renal carcinoma cells. Migration ability of 786-0 cells and ACHN cells was determined after the IgG expression was knockdown for 24 h by Transwell assay. Data represent the mean±SEM of cells of at least three random fields under microscope, and the experiment was repeated three times (*p<0.05).
Figure5
The invasion ability of renal carcinoma cells was also detected by specific siRNA for IgG. Invasion ability of 786-0 cells and ACHN cells was determined after the IgG expression was knockdown for 48 h by Matrigel assay. Data represent the mean±SEM of cells of at least three random fields under microscope, and the experiment was repeated three times (*p<0.05).
longer than that of patients with strong positive ('++' and '+++') IgG staining (p<0.05; figure 6 ). Cox multivariable analysis also showed that IgG strong positive staining (HR=3.494, p=0.0455) and histological grade ((HR=2.632, p=0.0089) were risk factors of poor prognosis for patients with cRCC (table 2) .
DISCUSSION
In this study, we found that IgG was significantly expressed in the cRCC cells and tissues, and IgG expression was found to be involved in the proliferation, migration and invasion of cRCC. Importantly, IgG expression was related to the poor differentiation, large tumour size and advanced clinical stage.
IgG has thus far been considered to be only produced in B cells and to only have an antibody function. Since Qiu et al 3 (1996) 18 first reported that the IgG was expressed in non-B-cell-derived cancer cells based on evidence supporting that the Ig's are not only expressed in B cells, they are also expressed in non-B cells. 3 4 7 19 Additionally, they are especially overexpressed in the cancer cells, including in many epithelial cancer cells and the mesenchymal tissue origin of cancer cells. 9 10 In this study, we further confirmed that IgG was significantly expressed in the primary cRCC cells and its derived cancer cell lines at the protein and mRNA levels by immunohistochemistry, western blot and RT-PCR. In addition, the adjacent normal kidney tissues, especially the renal tubular epithelial cells, could express the IgG. However, the function of IgG produced by normal kidney cells requires further investigation. Moreover, it was reported that the IgG expressed in cancer cells has growth-factor-like activity, which can promote the proliferation and survival of cancer cells, and is involved in the carcinogenesis of breast cancer. 20 In this study, we also found that cRCC cell-derived IgG can promote cell proliferation. Knock down of IgG induced the apoptosis in 786-0 cells, but not in the ACHN cells. We then determined whether IgG could affect the migration and invasion ability of cRCC cells with the same numbers in each group of 786-0 and ACHN cells by the Transwell and Matrigel assays. The results showed that renal carcinoma cell-derived IgG showed a significant promoting effect on cell migration and invasion in both 786-0 and ACHN cells. According to the apoptosis results, we concluded that IgG may be involved in the metastasis and prognosis of renal carcinoma cells while suppressing the interference of apoptosis. In addition, tumour metastasis is the leading cause of cancer mortality worldwide. The migration and invasion ability of cancer cells is a prerequisite for metastasis.
Additionally, the poorly differentiated cRCCs have a poor prognosis. However, to date, no independent prognosis factor has been found to be useful for predicting the prognosis of cRCC. In this study, we further analysed the relationship between IgG expression and the histological grade of cRCC. We unexpectedly found that IgG expression was significantly related to poor differentiation of cRCC.
Moreover, in our previous study, we found that IgG expression is strongly correlated with poor differentiation, local invasion, metastasis and poor prognosis in patients with lung adenocarcinoma, which suggested that IgG might serve as a new prognostic biomarker for lung adenocarcinom. 21 In the future, we will investigate the role of IgG in the prognosis of patients with cRCC. Furthermore, the clinical stage and tumour size are indicators for survival in cRCC. We also found that IgG was related to the clinical stage and tumour size of cRCC, suggesting that the IgG can be used to predict the prognosis of cRCC as a novel independent prognostic factor. Through the survival analysis, we found that the IgG expression was related to the patient survival period, which further confirmed that IgG could affect the patient prognosis. Cox multivariable analysis showed that IgG expression is a risk factor of poor prognosis for patients with cRCC.
In view of the expression of the IgG being correlated with the poor differentiation and poor prognosis of cRCCs, moreover, knockdown of IgG significantly inhibited the proliferation, migration and invasion of cRCC cell lines, which suggested that IgG recognised by RP215 may serve as a potential therapeutic target for cRCCs.
Overall, we found that IgG was overexpressed in cRCC and was involved in the proliferation, migration and invasion of cancer cells. IgG expression may serve as a potential target in cancer therapies and could be used for judging the prognosis. 
